Similarly, PARP1 expression affected the MFS in two out of three major pathological types of STS (Fig. S1): liposarcomas with 71% 5‐year MFS in the ‘PARP1‐low’ class vs 57% in the ‘PARP1‐high’ class (P = 3.17E‐02, log‐rank test) and undifferentiated sarcomas with respective 5‐year MFs equal to 80% vs 59% (P = 7.76E‐03, log‐rank test). Here, PARP1 is linked to telomere syndrome.